https://www.thelancet.com/pdfs/journals/lanpsy/PIIS2215-0366(16)30065-7.pdf

Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study

Chemistry and Biology of Mycotoxins and Related Fungal Metabolites

Simple indole alkaloids and those with a nonrearranged monoterpenoid unit

https://www.cell.com/trends/pharmacological-sciences/pdf/S0165-6147(08)00154-5.pdf

Serotonin research: contributions to understanding psychoses.

Psilocybin and related hallucinogenic compounds are increasingly used in human research. However, due to limited information about potential subjective side effects, the controlled medical use of these compounds has remained controversial. We therefore analysed acute, short- and long-term subjective effects of psilocybin in healthy humans by pooling raw data from eight double-blind placebo-controlled experimental studies conducted between 1999 and 2008. The analysis included 110 healthy subjects who had received 1-4 oral doses of psilocybin (45-315 µg/kg body weight). Although psilocybin dose-dependently induced profound changes in mood, perception, thought and self-experience, most subjects described the experience as pleasurable, enriching and non-threatening. Acute adverse drug reactions, characterized by strong dysphoria and/or anxiety/panic, occurred only in the two highest dose conditions in a relatively small proportion of subjects. All acute adverse drug reactions were successfully managed by providing interpersonal support and did not need psychopharmacological intervention. Follow-up questionnaires indicated no subsequent drug abuse, persisting perception disorders, prolonged psychosis or other long-term impairment of functioning in any of our subjects. The results suggest that the administration of moderate doses of psilocybin to healthy, high-functioning and well-prepared subjects in the context of a carefully monitored research environment is associated with an acceptable level of risk.

http://journals.sagepub.com/doi/pdf/10.1177/0269881110382466

Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies.

The psychotropically active principles of the Mexican hallucinogenic fungus Psilocybe maxicana HEIM have been isolated and obtained in crystalline form. The two new substances, which have been called psilocybin and psilocin, are present in the fruit bodies, the artificially cultivated mycelium and in the sclerotia. The dried mushroom contains 0.2 to 0.4 per cent psilocybin. Psilocin is present, at the most, in trace amounts only.

Psilocybin und Psilocin, zwei psychotrope Wirkstoffe aus mexikanischen Rauschpilzen

The structure of Psilocybin, the psychotropic active principle of the Mexican mushroomPsilocybe mexicana Heim, has been elucidated. Psilocybin is the phosphoric acid ester of 4-hydroxy-dimethyltryptamine. This structure was confirmed by total synthesis.

Elucidation of the structure and the synthesis of psilocybin

A stereospecific synthesis of ergotamine is described which confirms the postulated formula containing a cyclol structure. During this work it was also possible to determine the previously unknown configurations at the asymmetric centers C-2′ and C-12′.

Die Synthese und Stereochemie des Ergotamins. (58. Mitteilung über Mutterkornalkaloide

The total synthesis of the Ergot alkaloid Ergotamine is described.

The total synthesis of ergotamine

The total synthesis of ergosine, a naturally occurring ergot alkaloid, and of ergovaline, which contains valine as the variable amino acid of the peptide part and has not been found in nature yet, is described in accordance with the process developed for the synthesis of ergotamine.

H. Ott

Papers

Psilocybin und Psilocin, zwei psychotrope Wirkstoffe aus mexikanischen Rauschpilzen

Elucidation of the structure and the synthesis of psilocybin

Die Synthese und Stereochemie des Ergotamins. (58. Mitteilung über Mutterkornalkaloide

The total synthesis of ergotamine

Die Synthese des Ergosins und des Valin‐Analogen der Ergotamin‐Gruppe. 61. Mitteilung über Mutterkornalkaloide